Showing results (71-80 of 101) with videos related to
Sort By:
Pageof 11
Biorxiv : the Preprint Server for Biology|February 24, 2023
Oncogenic Kras G12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 + T cells dependent mannerKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.Cancer Discovery|February 13, 2020
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor MicroenvironmentPrasenjit Dey, Jun Li, Jianhua Zhang, et al.Cancers|October 16, 2024
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case SeriesAshwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.Nature Cancer|December 30, 2022
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancerPat Gulhati, Aislyn Schalck, Shan Jiang, et al.Cancer Cell|August 25, 2023
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cellsKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.Nature Communications|April 17, 2023
Ether phospholipids are required for mitochondrial reactive oxygen species homeostasisZiheng Chen, I-Lin Ho, Melinda Soeung, et al.Cell Reports. Medicine|July 27, 2025
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMadelaine S Theardy, Mitsunobu Takeda, Alexey Sorokin, et al.Biorxiv : the Preprint Server for Biology|August 30, 2024
Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMitsunobu Takeda, Madelaine S Theardy, Alexey Sorokin, et al.Nature Communications|May 11, 2026
All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancerChing-Fei Li, Yongkun Wei, Heng-Huan Lee, et al.Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.Pageof 11